Key considerations for using real-world data to evaluate the clinical and economic value of drugs
With the acceleration of global innovative drug development,selecting safe,effective,and cost-effective products from numerous drugs has posed new challenges for the decision-making process of medical insurance drug access and dynamic updating of insurance directory.Real-world data(RWD)provides a new perspective for evaluation of clinical and economic value of drugs,but there are still uncertainties regarding the scope,quality standards,and evidence categories of RWD that can be used.Based on the current status of domestic and international RWD supporting the assessment of the clinical and economic value of drugs,this paper,in collaboration with national RWD and healthcare experts,has developed the key considerations for using real-world data to evaluate the clinical and economic value of drugs.This paper first clarifies the scope of RWD that can be used to evaluate the clinical and economic value of drugs evaluate;secondly,provides specific requirements and guidance on data attribution,data governance,and quality standards for RWD;finally,summarizes the evidence categories of RWD supporting evaluate the clinical and economic value of drugs evaluate.
Real-world dataReal-world evidenceClinical value of drugsEconomic value of drugs
万方数据
维普
